Annual ROE
-250.72%
-192.53%-330.86%
September 30, 2024
Summary
- As of February 12, 2025, ARWR annual return on equity is -250.72%, with the most recent change of -192.53% (-330.86%) on September 30, 2024.
- During the last 3 years, ARWR annual ROE has fallen by -218.36% (-674.78%).
- ARWR annual ROE is now -725.71% below its all-time high of 40.07%, reached on September 30, 2019.
Performance
ARWR ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-206.69%
-33.79%-19.54%
September 30, 2024
Summary
- As of February 12, 2025, ARWR quarterly return on equity is -206.69%, with the most recent change of -33.79% (-19.54%) on September 30, 2024.
- Over the past year, ARWR quarterly ROE has dropped by -59.61% (-40.53%).
- ARWR quarterly ROE is now -669.86% below its all-time high of 36.27%, reached on September 30, 2019.
Performance
ARWR Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
ARWR ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -330.9% | -40.5% |
| 3 y3 years | -674.8% | -547.9% |
| 5 y5 years | -725.7% | -547.9% |
ARWR ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -674.8% | at low | -682.3% | at low |
| 5 y | 5-year | -725.7% | at low | -1141.3% | at low |
| alltime | all time | -725.7% | at low | -669.9% | +85.4% |
Arrowhead Pharmaceuticals ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | -250.72%(+330.9%) | -206.69%(+19.5%) |
| Jun 2024 | - | -172.90%(+17.6%) |
| Mar 2024 | - | -147.08%(+68.9%) |
| Dec 2023 | - | -87.08%(+65.4%) |
| Sep 2023 | -58.19%(+36.7%) | -52.66%(+24.2%) |
| Jun 2023 | - | -42.39%(+24.5%) |
| Mar 2023 | - | -34.04%(-6.9%) |
| Dec 2022 | - | -36.55%(-11.7%) |
| Sep 2022 | -42.57%(+31.6%) | -41.40%(+15.4%) |
| Jun 2022 | - | -35.89%(+35.8%) |
| Mar 2022 | - | -26.42%(-38.8%) |
| Dec 2021 | - | -43.19%(+35.4%) |
| Sep 2021 | -32.36%(+35.1%) | -31.90%(+16.1%) |
| Jun 2021 | - | -27.48%(+17.7%) |
| Mar 2021 | - | -23.34%(+9.3%) |
| Dec 2020 | - | -21.36%(+10.7%) |
| Sep 2020 | -23.96%(-159.8%) | -19.29%(+209.1%) |
| Jun 2020 | - | -6.24%(-317.4%) |
| Mar 2020 | - | 2.87%(-85.5%) |
| Dec 2019 | - | 19.85%(-45.3%) |
| Sep 2019 | 40.07%(-164.8%) | 36.27%(+26.7%) |
| Jun 2019 | - | 28.63%(+308.4%) |
| Mar 2019 | - | 7.01%(-126.5%) |
| Dec 2018 | - | -26.44%(-55.2%) |
| Sep 2018 | -61.84%(+58.2%) | -58.96%(-1.2%) |
| Jun 2018 | - | -59.66%(+20.5%) |
| Mar 2018 | - | -49.52%(+20.3%) |
| Dec 2017 | - | -41.16%(+9.2%) |
| Sep 2017 | -39.09%(-51.1%) | -37.70%(-28.6%) |
| Jun 2017 | - | -52.78%(-26.0%) |
| Mar 2017 | - | -71.34%(-20.0%) |
| Dec 2016 | - | -89.18%(-6.1%) |
| Sep 2016 | -79.87%(+19.7%) | -94.95%(+5.1%) |
| Jun 2016 | - | -90.37%(+23.3%) |
| Mar 2016 | - | -73.30%(+3.0%) |
| Dec 2015 | - | -71.17%(+7.8%) |
| Sep 2015 | -66.72%(+9.1%) | -66.02%(+13.8%) |
| Jun 2015 | - | -58.01%(+13.0%) |
| Mar 2015 | - | -51.32%(+11.7%) |
| Dec 2014 | - | -45.95%(+1.6%) |
| Sep 2014 | -61.16%(-66.1%) | -45.24%(-6.5%) |
| Jun 2014 | - | -48.41%(-27.2%) |
| Mar 2014 | - | -66.53%(-45.8%) |
| Dec 2013 | - | -122.78%(-37.5%) |
| Sep 2013 | -180.31%(-8.8%) | -196.58%(+7.0%) |
| Jun 2013 | - | -183.80%(-40.1%) |
| Mar 2013 | - | -307.01%(+37.8%) |
| Dec 2012 | - | -222.84%(+20.5%) |
| Sep 2012 | -197.69% | -184.87%(+17.1%) |
| Jun 2012 | - | -157.81%(+59.3%) |
| Mar 2012 | - | -99.07%(+177.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | - | -35.76%(+16.0%) |
| Sep 2011 | -30.32%(-66.0%) | -30.84%(+24.6%) |
| Jun 2011 | - | -24.75%(+132.0%) |
| Mar 2011 | - | -10.67%(-86.1%) |
| Dec 2010 | - | -76.89%(-8.3%) |
| Sep 2010 | -89.27%(-60.3%) | -83.88%(-30.3%) |
| Jun 2010 | - | -120.28%(-46.2%) |
| Mar 2010 | - | -223.45%(-28.5%) |
| Dec 2009 | - | -312.33%(-15.0%) |
| Sep 2009 | -225.03%(+61.0%) | -367.35%(+12.4%) |
| Jun 2009 | - | -326.81%(+23.7%) |
| Mar 2009 | - | -264.12%(+47.2%) |
| Dec 2008 | - | -179.42%(+38.7%) |
| Sep 2008 | -139.78%(+35.6%) | -129.32%(+25.5%) |
| Jun 2008 | - | -103.01%(-9.6%) |
| Mar 2008 | - | -113.98%(+6.7%) |
| Dec 2007 | - | -106.82%(+7.8%) |
| Sep 2007 | -103.10%(+61.8%) | -99.13%(+12.6%) |
| Jun 2007 | - | -88.03%(+48.5%) |
| Mar 2007 | - | -59.27%(+4.2%) |
| Dec 2006 | - | -56.86%(-0.2%) |
| Sep 2006 | -63.73%(+82.4%) | -56.98%(+21.6%) |
| Jun 2006 | - | -46.84%(-8.4%) |
| Mar 2006 | - | -51.11%(+29.4%) |
| Dec 2005 | - | -39.51%(+7.8%) |
| Sep 2005 | -34.94%(-12.6%) | -36.64%(+3.2%) |
| Jun 2005 | - | -35.49%(+33.4%) |
| Mar 2005 | - | -26.61%(-36.6%) |
| Dec 2004 | - | -42.00%(+26.2%) |
| Sep 2004 | -39.98%(+495.8%) | -33.27%(+82.6%) |
| Jun 2004 | - | -18.22%(+28.6%) |
| Mar 2004 | - | -14.17%(-99.0%) |
| Dec 2003 | - | -1412.97%(<-9900.0%) |
| Sep 2003 | -6.71%(-142.3%) | 10.50%(-39.9%) |
| Jun 2003 | - | 17.46%(-14.6%) |
| Mar 2003 | - | 20.45%(+34.3%) |
| Dec 2002 | - | 15.23%(-10.9%) |
| Sep 2002 | 15.88%(+11.5%) | 17.10%(+6.0%) |
| Jun 2002 | - | 16.13%(+27.8%) |
| Mar 2002 | - | 12.62%(-22.3%) |
| Dec 2001 | - | 16.24%(+7.5%) |
| Sep 2001 | 14.24%(+16.8%) | 15.10%(+98.9%) |
| Jun 2001 | - | 7.59%(-23.0%) |
| Mar 2001 | - | 9.86%(-4.5%) |
| Dec 2000 | - | 10.33%(-16.4%) |
| Sep 2000 | 12.19%(-120.5%) | 12.36%(-20.6%) |
| Jun 2000 | - | 15.56%(+46.4%) |
| Mar 2000 | - | 10.63%(+84.5%) |
| Dec 1999 | - | 5.76% |
| Sep 1999 | -59.53%(-1109.0%) | - |
| Sep 1998 | 5.90%(-82.2%) | - |
| Sep 1997 | 33.17% | - |
FAQ
- What is Arrowhead Pharmaceuticals annual return on equity?
- What is the all time high annual ROE for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual ROE year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly return on equity?
- What is the all time high quarterly ROE for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly ROE year-on-year change?
What is Arrowhead Pharmaceuticals annual return on equity?
The current annual ROE of ARWR is -250.72%
What is the all time high annual ROE for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual return on equity is 40.07%
What is Arrowhead Pharmaceuticals annual ROE year-on-year change?
Over the past year, ARWR annual return on equity has changed by -192.53% (-330.86%)
What is Arrowhead Pharmaceuticals quarterly return on equity?
The current quarterly ROE of ARWR is -206.69%
What is the all time high quarterly ROE for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly return on equity is 36.27%
What is Arrowhead Pharmaceuticals quarterly ROE year-on-year change?
Over the past year, ARWR quarterly return on equity has changed by -59.61% (-40.53%)